KRAS G12C MUTATION ADVANCED SOLID TUMOR

Clinical trials for KRAS G12C MUTATION ADVANCED SOLID TUMOR explained in plain language.

Never miss a new study

Get alerted when new KRAS G12C MUTATION ADVANCED SOLID TUMOR trials appear

Sign up with your email to follow new studies for KRAS G12C MUTATION ADVANCED SOLID TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New pill targets hard-to-treat cancers with KRAS mutation

Disease control Not yet recruiting

This early-stage study tests a new drug, HS-10541, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The drug is given alone or with other cancer treatments. The main goals are to check safety, find the right dose, and see if it shrinks tu…

Matched conditions: KRAS G12C MUTATION ADVANCED SOLID TUMOR

Phase: PHASE1 • Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. • Aim: Disease control

Last updated Jun 16, 2026 12:53 UTC

KRAS G12C MUTATION ADVANCED SOLID TUMOR

Get alerted when new KRAS G12C MUTATION ADVANCED SOLID TUMOR trials appear

New pill targets hard-to-treat cancers with KRAS mutation